



ASX ANNOUNCEMENT

1 August 2005

HeartWare Completes Final HVAD Implant in GLP Study

HeartWare is pleased to announce that surgeons at the Texas Heart Institute last week performed a sixth successful pre-clinical implantation of the HeartWare HVAD under Good Laboratory Practice (“GLP”) conditions. HeartWare expects this to be the final implant required under the GLP study.

Also last week, a further two HVAD GLP studies reached the 90 days required by the pre-clinical protocol. This brings to four the number of HVAD devices which have successfully concluded the 90 days GLP implant period. In all four cases, analysis of the device along with pathology tests conducted at the Texas Heart Institute indicates that the pumps performed very well. The fifth GLP study will be concluded in August.

HeartWare CEO, Mr Stuart McConchie, commented:

“These excellent pre-clinical results indicate that the HVAD continues to perform according to design. HeartWare remains on track to commence clinical trials in the first quarter of 2006 as forecast in our Prospectus. The HeartWare team in both Miami and Sydney, along with the staff at the Texas Heart Institute, should be commended for their dedication and skill in achieving these outstanding results.

The HVAD continues to demonstrate that HeartWare’s patented technology represents the state-of-the-art in implantable mechanical cardiac assistance. Together with the BiVAD procedure performed by Dr Frazier at the Texas Heart Institute last week, HeartWare has reinforced the opportunity for its products to address the full range of clinical applications for mechanical cardiac assistance”.

About HeartWare

HeartWare is developing a family of proprietary circulatory heart assist devices to treat patients with congestive heart failure. Heart failure affects 10 million people globally, with over one million new patients diagnosed every year.

HeartWare’s first left ventricular assist device, the HVAD, is expected to commence human clinical trials in early 2006, with first sales planned for 2007. With a volume of 45cc, the HVAD is substantially smaller than other “third generation” full output pumps in development, giving rise to significant potential clinical advantages. Further information on HeartWare is available at www.heartware.com.au

For more information:

Howard Leibman
HeartWare Limited
(02) 8215 7604 / 0402 440644

Paula Hannaford / Stuart Barton
Gavin Anderson & Company
0413 940 180 / 0404 054 857